Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Alsar, JS; de la Tabla, AGO; Moran, LO; Martin, AJM.

Treatment modalities in cancer-associated venous thromboembolism (VTE)

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2022; 35(1): Nº de citas: 2 [doi:10.1016/j.beha.2022.101354]

Lopez-Tarruella, S; Echavarria, I; Jerez, Y; Herrero, B; Gamez, S; Martin, M.

How we treat HR-positive, HER2-negative early breast cancer

Future Oncology. 2022; 18(8): 1003-1022 Nº de citas: 11 [doi:10.2217/fon-2021-0668]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(3): 483-494 Nº de citas: 31 [doi:10.1007/s12094-021-02708-4]

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arija, JA; Marin, MR; Lisyanskaya, A; Poka, RL; Markowska, J; Cebotaru, C; Herraez, AC; Colombo, N; Kutarska, E; Hall, M; Jacobs, A; Ahrens-Fath, I; Baumeister, H; Zurlo, A; Sehouli, J.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

Esmo Open. 2022; 7(1): Nº de citas: 8 [doi:10.1016/j.esmoop.2021.100311]

Calvo, A; Gonzalez-Hidalgo, M; Terleira, A; Fernandez, N; Portoles, A.

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers

Journal of Clinical Medicine. 2022; 11(4): Nº de citas: 1 [doi:10.3390/jcm11041141]

Schoffski, P; Tan, DSW; Martin, M; Ochoa-de-Olza, M; Sarantopoulos, J; Carvajal, RD; Kyi, C; Esaki, T; Prawira, A; Akerley, W; De Braud, F; Hui, RN; Zhang, T; Soo, RA; Maur, M; Weickhardt, A; Krauss, J; Deschler-Baier, B; Lau, A; Samant, TS; Longmire, T; Chowdhury, NR; Sabatos-Peyton, CA; Patel, N; Ramesh, R; Hu, TC; Carion, A; Gusenleitner, D; Yerramilli-Rao, P; Askoxylakis, V; Kwak, EL; Hong, DS.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer. 2022; 10(2): Nº de citas: 127 [doi:10.1136/jitc-2021-003776]

Muino, CB; Martin, M; del Monte-Millan, M; Garcia-Saenz, JA; Lopez-Tarruella, S.

HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cancers. 2022; 14(3): Nº de citas: 2 [doi:10.3390/cancers14030512]

Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(3): 282-293 Nº de citas: 167 [doi:10.1200/JCO.21.02554]

Lenz, HJ; Van Cutsem, E; Limon, ML; Wong, KYM; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Luppi, G; Cardin, DB; Dragovich, T; Shah, U; Abdullaev, S; Gricar, J; Ledeine, JM; Overman, MJ; Lonardi, S.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 161-170 Nº de citas: 478 [doi:10.1200/JCO.21.01015]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Butler, MO; Hill, A; Marquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bas, T; Ritchings, C; Larkin, J; Hodi, FS.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 127-137 Nº de citas: 798 [doi:10.1200/JCO.21.02229]

Alfano, F; Cordero-Grande, L; Ortuno, JE; Garcia, KF; Garcia-Sevilla, M; Zamora, OB; Conde, MH; Lizarraga, S; Santos, A; Pascau, J; Ledesma-Carbayo, MJ.

Breast Tumor Localization by Prone to Supine Landmark Driven Registration for Surgical Planning

IEEE Access. 2022; 10: 122901-122911 Nº de citas: 3 [doi:10.1109/ACCESS.2022.3223658]

Perez-Hernandez, C; Canovas, ML; Carmona-Bayonas, A; Escobar, Y; Margarit, C; Cervantes, JFM; Quintanar, T; Alfonso, AS; Virizuela, J.

A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

Journal of Pain Research. 2022; 15: 2181-2196 Nº de citas: 3 [doi:10.2147/JPR.S365351]

Yau, C; Osdoit, M; van der Noordaa, M; Shad, S; Wei, J; de Croze, D; Harny, AS; Lae, M; Reyal, F; Sonke, GS; Steenbruggen, TG; van Seijen, M; Wesseling, J; Martin, M; del Monte-Millan, M; Lopez-Tarruella, S; Boughey, JC; Goetz, MP; Hoskin, T; Gould, R; Valero, V; Edge, SB; Abraham, JE; Bartlett, JMS; Caldas, C; Dunn, J; Earl, H; Hayward, L; Hiller, L; Provenzano, E; Sammut, SJ; Thomas, JS; Cameron, D; Graham, A; Hail, P; Mackintosh, L; Fan, F; Godwin, AK; Schwensen, K; Sharma, P; DeMichele, AM; Cole, K; Pusztai, L; Kim, MO; Veer, LJV; Esserman, LJ; Symmans, WF.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

LANCET ONCOLOGY. 2022; 23(1): 149-160 Nº de citas: 295 [doi:10.1016/S1470-2045(21)00589-1]

Calvo-Lopez, T; Paz-Cabezas, M; Llovet, P; Ibanez, MD; Sastre, J; Alonso-Orduna, V; Vieitez, JM; Yubero, A; Vera, R; Asensio-Martinez, E; Garcia-Alfonso, P; Aranda, E; Diaz-Rubio, E; Perez-Villamil, B.

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Cancer Biomarkers. 2022; 34(2): 201-210 Nº de citas: 4 [doi:10.3233/CBM-210353]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2022; 17(12): 1467-1473 Nº de citas: 10 [doi:10.1080/17425255.2021.2027908]

Munoz, AJ; de Toro, M; Ortega, L; Lopez, C; Gutierrez, A; Juliao, DS; Arregui, M; Lobato, N; Echavarria, I; Marquez-Rodas, I; Martin, M.

Venous thromboembolism incidence in cancer patients with germline BRCA mutations

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(1): 154-158 Nº de citas: 1 [doi:10.1007/s12094-021-02678-7]

Kalinsky, K; Barlow, WE; Gralow, JR; Meric-Bernstam, F; Albain, KS; Hayes, DF; Lin, NU; Perez, EA; Goldstein, LJ; Chia, SKL; Dhesy-Thind, S; Rastogi, P; Alba, E; Delaloge, S; Martin, M; Kelly, CM; Ruiz-Borrego, M; Gil-Gil, M; Arce-Salinas, CH; Brain, EGC; Lee, ES; Pierga, JY; Bermejo, B; Ramos-Vazquez, M; Jung, KH; Ferrero, JM; Schott, AF; Shak, S; Sharma, P; Lew, DL; Miao, J; Tripathy, D; Pusztai, L; Hortobagyi, GN.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. 2021; 385(25): 2336-2347 Nº de citas: 560 [doi:10.1056/NEJMoa2108873]

Bouza, E; Jimenez, MM; Alemany, L; Arribas, J; Banares, R; Barragan, MB; Bouza, JME; Felip, E; Fernandez-Capetillo, O; Gracia, D; Lopez-Velez, R; Mollar, JB; Munoz, P; Paz-Ares, L; Torne, A; Tovar, J; Valencia, E; Palomo, E.

Overview of virus and cancer relationships. Position paper

REVISTA ESPANOLA DE QUIMIOTERAPIA. 2021; 34(6): 525-555 Nº de citas: 6 [doi:10.37201/req/058.2021]